Thomas Haughey
Known title: DirectorCIK: 0001272247
Thomas Haughey's purchase track record
Thomas Haughey has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 12/6/2021 | ANIP | $98K | -10.5% | -28.5% | -10.2% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| ANIP | ▼ Sell | Open Market | 2,000 | $162K | 6/8/2026 | View on chart |
| ANIP | ▲ Buy | Grant | 4,357 | $0 | 5/21/2026 | View on chart |
| ANIP | ▼ Sell | Open Market | 19,341 | $1.7M | 8/12/2025 | View on chart |
| ANIP | ▲ Buy | Grant | 4,336 | $0 | 5/22/2025 | View on chart |
| ANIP | ▲ Buy | Grant | 4,410 | $0 | 5/21/2024 | View on chart |
| ANIP | ▲ Buy | Grant | 6,865 | $0 | 5/23/2023 | View on chart |
| ANIP | ▲ Buy | Grant | 10,049 | $0 | 4/27/2022 | View on chart |
| ANIP | ▲ Buy | Open Market | 2,500 | $98K | 12/6/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
ANI Pharmaceuticals Reports Positive Phase 4 Trial Results
ANI Pharmaceuticals announced encouraging results from its Phase 4 open‑label SYNCHRONICITY study, presented at the American Academy of Ophthalmology meeting. The company’s focus on this therapy comes amid a recent FDA pause on generic everolimus, which may alter market perception of its product line. Analysts note ANI’s competitive advantages, though the stock remains near its 52‑week low, suggesting cautious evaluation.
ANI Pharmaceuticals Reports Positive Phase 4 Trial Results. ANI Pharmaceuticals announced encouraging results from its Phase 4 open‑label SYNCHRONICITY study, presented at the American Academy of Ophthalmology meeting. The company’s focus on this therapy comes amid a recent FDA pause on generic everolimus, which may alter market perception of its product line. Analysts note ANI’s competitive advantages, though the stock remains near its 52‑week low, suggesting cautious evaluation.